Prior research suggest gender-specific differences in symptom levels and comorbidity prevalence among patients with COPD. Investigators conducted an analysis to determine whether the relationship between these characteristics is...
Read MoreAlthough data indicate that e-cigarettes are the most commonly used tobacco product among adolescents and young adults (AYAs), frequent co-use with combustible cigarettes and cannabis products causes difficulty in disentangling...
Read MorePrior research provides unclear results on the benefits of omega-3 fatty acids for the prevention of cardiovascular outcomes in patients with high cardiovascular risk. To determine the association of plasma levels of...
Read MoreUnited States guidelines suggest any aspirin dose between 81 mg and 325 mg daily for patients with coronary heart disease, while European guidelines that recommend 81 mg daily are mainly based on observational data and expert...
Read MoreWith little known regarding psychological distress and residual risk of future cardiovascular events in young and middle-aged patients with a recent myocardial infarction (MI), researchers divided patients aged 18-61 with an MI...
Read MorePrevious studies suggest that endovascular renal denervation reduces blood pressure (BP) in patients with mild-to-moderate hypertension. However, its efficacy in patients with resistant hypertension remains unknow. To assess the...
Read MoreAlthough research indicates that older adults hospitalized with acute decompensated heart failure (HF) have high rates of poor quality of life, delayed recovery, physical frailty, and frequent rehospitalization, well-established...
Read More
“For children with exstrophy-epispadias complex (EEC), a spectrum of genitourinary malformation,...
Read MoreIn the phase 2 NANT2011-01 trial, levels of circulating tumor DNA (ctDNA) were evaluated during treatment. In patients with a clinical response, ctDNA becomes undetectable over time. Neuroblastoma is the most common extracranial...
Read MoreMirvetuximab soravtansine, a folate receptor-targeting antibody-drug conjugate, in combination with bevacizumab, demonstrated impressive anti-cancer activity in the phase 1b FORWARD II trial. Mirvetuximab soravtansine (MIRV) is...
Read MoreFirst results from the phase 3 PEACE-1 trial show that adding abiraterone to androgen deprivation therapy (ADT) plus docetaxel significantly improves progression-free survival in patients who present with de novo metastatic...
Read MoreFirst results of the phase 3 RELATIVITY-047 trial validate the efficacy of dual checkpoint blockade demonstrated with the LAG-3 inhibitor relatlimab and nivolumab in patients with advanced melanoma. Lymphocyte-activation gene 3...
Read MoreAn exploratory post-hoc pooled analysis of three phase 3 trials with atezolizumab in patients with stage IV non-small cell lung cancer (NSCLC) – IMpower130, IMpower132, and IMpower150 – shows longer overall survival for patients...
Read MoreAnalysis of 1,000 patients in the MINDACT trial identifies patients with ultra-low risk for distant recurrence. These patients could be candidates for further de-escalation of treatment. Gene signatures have proven successful in...
Read MorePatritumab deruxtecan (HER3-DXd), an antibody drug conjugate consisting of a monoclonal antibody to HER3 attached to a topoisomerase I, demonstrates anti-tumour activity across various EGFR TKI resistance mechanisms in heavily...
Read MoreAfter initial results over 5 years ago, long-term follow-up data from 3 clinical trials – CheckMate 067, COLUMBUS, and ABC – show a durable and sustained clinical benefit for patients with melanoma. In the phase 3 CheckMate 067...
Read MoreFirst-line treatment of patients with microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) with pembrolizumab improves overall survival, but the prespecified threshold for...
Read MoreFirst results of the phase 3 KEYNOTE 564 trial show that adjuvant therapy with pembrolizumab after nephrectomy enhances disease-free survival of patients treated for locoregional clear cell renal cell cancer (RCC). Nephrectomy...
Read MoreResults of the randomized, phase 3 OUTBACK trial do not support the use of adjuvant chemotherapy after chemoradiation in women with locally advanced cervical cancer. At 5 years, both overall and progression-free survival were...
Read MoreA first interim analysis of the OlympiA trial demonstrates significantly improved invasive disease-free survival in patients with high risk, HER2-negative, germline BRCA1/2-mutated primary breast cancer after 1 year of adjuvant...
Read More
